HDAC Inhibitors may be Doing More Harm Than Good in HIV Eradication

by Kathy Jones on  August 15, 2014 at 11:14 PM AIDS/HIV News
RSS Email Print This Page Comment bookmark
Font : A-A+

While Histone deacetylase (HDAC) inhibitors have been found to be effective in 'flushing out' HIV from infected cells, a new study published in the journal PLOS Pathogens suggests that they may instead be hindering HIV eradication by suppressing CTL activity and thereby compromising the 'kill' part of the two-pronged 'flush and kill' strategy.
 HDAC Inhibitors may be Doing More Harm Than Good in HIV Eradication
HDAC Inhibitors may be Doing More Harm Than Good in HIV Eradication

At least three different HDAC inhibitors, romidepsin, panobinostat, and SAHA, are under investigation as flushing agents. The individual drugs differ somewhat in their specificity for the 18 known human HDACs, and are also known to interact with other cellular factors and to alter the function of immune cells. Arguing that "this high degree of complexity both in terms of immunological outcomes and underlying mechanisms, necessitates that HDAC inhibitors be studied in a context that is matched to their intended utility", Brad Jones, from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Boston, USA, and colleagues set out to test whether the three drugs affected the ability of CTL to eliminate HIV-infected target cells.

While the individual effects of the drugs on virus-specific CTL differ somewhat depending on specific assays, schedules, and doses, treatment with any of the three HDAC inhibitors impaired the ability of CTL to kill HIV-infected immune cells. All three drugs also rapidly suppressed CTL production of the key immune mediator interferon gamma.

Discussing the limitations of the study, the researchers state that, because their assays all involve drug treatment of CTL in cell culture settings, the extent to which HDAC inhibitors impact CTL function in HIV infected patients remains unknown. Consequently, they hope that their results will "motivate the incorporation of assays measuring ex-vivo T-cell function into ongoing and planned clinical trials of HDAC inhibitors, and that immunosuppression will be considered as a potential factor limiting the effectiveness of any observed outcomes". They also highlight the potential broader risk of treating HIV-positive individuals—whose immune systems remain compromised even on antiretroviral therapy—with HDAC inhibitors that have shown immunosuppressive activity in several studies, including this one.



Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Oral Health And AIDS AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs Prostitution: Fresh Stakes in the Oldest Trade HIV Symptom 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive